Akero Therapeutics, Inc.
AKRONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for AKRO. That does not mean none is planned.
Get an email about AKRO's next catalysts
Track Akero Therapeutics (AKRO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EFX | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Akero Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Akero Therapeutics, Inc.'s (AKRO) pipeline across Phase 2. Its lead program is EFX (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Akero Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Akero Therapeutics, Inc. (AKRO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AKRO biotech catalysts?→
Add AKRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Akero Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.